NASDAQ$TMCI
Treace Medical Concepts Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Treace Medical Concepts reported financial results, showing revenue increase and strategic investments.
Treace Medical Concepts reported a strong fourth quarter with a 39% increase in revenue compared to the same period last year, driven by the bunion-focused direct sales channel and direct-to-consumer programs. The company's gross margin also increased to 81.1%.
- Revenue of $33.4 million, a 39% increase over the same period last year and a 55% increase sequentially.
- Gross margin of 81.1%, an increase of 220 basis points from the same period last year.
- Increased strategic investments in sales and marketing programs, including expanded direct sales channel and direct-to-consumer (DTC) campaigns, as well as R&D programs for product innovations.
- Fourth quarter revenue contribution from bunion-focused direct sales channel was 58% of sales, an increase from an average of 39% in the fourth quarter 2020.
Headline financials
Revenue & EPS history
Treace · Revenue · Quarterly
$33.4M
Forward guidance
Treace expects revenue for the full year 2022 to range from $125 million to $130 million, which represents approximately 32% to 38% growth over the Company’s 2021 revenue.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
-5.8%
Avg return
Earnings day
-5.9%
Avg return
5 days after
-3.7%
Avg return
30 days after
33%
7 / 21 earnings
Positive
+43.3%
Q3 2024
Best reaction
-62.8%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.7% | +31.8% | +82.3% | |
| Q4 2025 | -11.0% | -30.0% | -41.9% | |
| Q3 2025 | -28.6% | -46.6% | -56.0% | |
| Q1 2025 | -9.5% | -10.9% | -22.9% | |
| Q4 2024 | -2.1% | +0.0% | -7.4% | |
| Q3 2024 | +43.3% | +48.1% | +42.7% | |
| Q2 2024 | +2.7% | -8.5% | -13.9% | |
| Q1 2024 | -62.8% | -60.9% | -45.5% | |
| Q4 2023 | -5.7% | -6.4% | -8.9% | |
| Q3 2023 | -42.1% | -32.0% | -11.4% | |
| Q2 2023 | -16.9% | -20.3% | -31.3% | |
| Q1 2023 | -5.5% | -4.9% | -0.9% | |
| Q4 2022 | +21.1% | +19.0% | +37.5% | |
| Q3 2022 | +1.9% | +16.1% | +13.7% | |
| Q2 2022 | -1.3% | +1.0% | +10.1% | |
| Q1 2022 | -14.4% | -30.2% | -9.3% | |
| Q4 2021 | -1.0% | -7.4% | -5.7% | |
| Q3 2021 | -0.8% | -6.6% | -28.5% | |
| Q2 2021 | -3.3% | -5.9% | -3.2% | |
| Q4 2020 | +4.7% | +14.9% | +11.5% | |
| Q1 2021 | +4.7% | +14.9% | +11.5% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro